Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.

ABSTRACT:

Background

In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo.

Methods

From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were cl

SUBMITTER: McNeil JJ 

PROVIDER: S-EPMC6433466 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature